Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
17.68
-0.02 (-0.11%)
Jan 29, 2026, 1:11 PM EST - Market open
Dyne Therapeutics Employees
Dyne Therapeutics had 240 employees as of September 30, 2025. The number of employees increased by 67 or 38.73% compared to the same quarter last year.
Employees
240
Change
67
Growth
38.73%
Revenue / Employee
n/a
Profits / Employee
-$1,765,838
Market Cap
2.91B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 240 | 67 | 38.73% |
| Jun 30, 2025 | 206 | 54 | 35.53% |
| Mar 31, 2025 | 192 | 49 | 34.27% |
| Dec 31, 2024 | 191 | 50 | 35.46% |
| Sep 30, 2024 | 173 | 37 | 27.21% |
| Jun 30, 2024 | 152 | 18 | 13.43% |
| Mar 31, 2024 | 143 | 21 | 17.21% |
| Dec 31, 2023 | 141 | 22 | 18.49% |
| Sep 30, 2023 | 136 | 21 | 18.26% |
| Jun 30, 2023 | 134 | 26 | 24.07% |
| Mar 31, 2023 | 122 | 26 | 27.08% |
| Dec 31, 2022 | 119 | 26 | 27.96% |
| Sep 30, 2022 | 115 | 27 | 30.68% |
| Jun 30, 2022 | 108 | 37 | 52.11% |
| Mar 31, 2022 | 96 | 40 | 71.43% |
| Dec 31, 2021 | 93 | 46 | 97.87% |
| Sep 30, 2021 | 88 | 52 | 144.44% |
| Jun 30, 2021 | 71 | 34 | 91.89% |
| Mar 31, 2021 | 56 | 19 | 51.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Apellis Pharmaceuticals | 710 |
| Adaptive Biotechnologies | 619 |
| Beam Therapeutics | 510 |
| Tarsus Pharmaceuticals | 323 |
| Catalyst Pharmaceuticals | 181 |
| Immunome | 168 |
| Viridian Therapeutics | 143 |
| Disc Medicine | 142 |
DYN News
- 2 days ago - Dyne Therapeutics: 2026 Catalysts Point To Further Upside - Seeking Alpha
- 9 days ago - Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 - GlobeNewsWire
- 14 days ago - Dyne Therapeutics, Inc. (DYN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 22 days ago - Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Dyne Therapeutics Appoints Vikram Karnani to Board of Directors - GlobeNewsWire
- 6 weeks ago - Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics: Why The $350M Public Offering Was Critical - Seeking Alpha
- 7 weeks ago - Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - GlobeNewsWire